This Issue contains three SXSW-inspired musings or updates. The first, and most substantial, looks ahead to just one facet of the potential patient access challenges for MDMA-assisted therapy; the second briefly covers comments and unpublished analysis shared by Rick Doblin; and, the third looks at synthetic vs. whole-mushroom psilocybin.
It also contains brief coverage of a number of other developments, including significant fundraising activity by MindMed and Cybin, as well as the launch of Usona Institute’s Phase 3 study…
Featured content in this Issue:
- Looking Ahead at Patient Access to MDMA-Assisted Therapy
- Rick Doblin on the ‘Future of Psychedelics’
- Whole Mushroom vs. Synthetic Psilocybin
- Usona Launches Phase 3 Study of Psilocybin for Major Depressive Disorder
- MindMed and Cybin Attract Investors with Breakthrough Therapy Designations
- Other News; In Case You Missed It
Companies, organisations and drug candidates mentioned in this Bulletin: Lykos Therapeutics, MDMA-assisted therapy; Usona Institute; MindMed; Cybin; CYB004.
This content is for Pα+ Subscribers
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
